The Library

Organometallic iridium(III) cyclopentadienyl anticancer complexes containing C,N-chelating ligands

Tools

Liu, Zhe (Researcher in chemistry), Habtemariam, Abraha, Pizarro, Ana M., Clarkson, Guy J. and Sadler, P. J.. (2011) Organometallic iridium(III) cyclopentadienyl anticancer complexes containing C,N-chelating ligands. Organometallics, Vol.30 (No.17). pp. 4702-4710. ISSN 0276-7333

Preview

Text
WRAP_Sadler_180811-15_sadler_om2011-005468.pdf - Accepted Version
Download (851Kb)

Official URL: http://dx.doi.org/10.1021/om2005468

Abstract

Organometallic IrIII cyclopentadienyl complexes [(η5-Cpx)Ir(CN)Cl] {Cpx = Cp*, CN = 2-(p-tolyl)pyridine (1), 2-phenylquinoline (2), 2-(2,4-difluorophenyl)pyridine (3), Cpx = tetramethyl(phenyl)cyclopentadienyl (Cpxph), CN = 2-phenylpyridine (4), and Cpx = tetramethyl(biphenyl)cyclopentadienyl (Cpxbiph), CN = 2-phenylpyridine (5)} have been synthesized and characterized. The X-ray crystal structures of 2 and 5 have been determined and show typical “piano-stool” geometry. All the complexes hydrolyzed rapidly in aqueous solution (<5 min) even at 278 K. The pKa values of the aqua adducts 1A–5A are in the range 8.31–8.87 and follow the order 1A > 2A > 4A > 5A ≈ 3A. Hydroxo-bridged dimers {[(η5-Cpx)Ir]2(μ-OD)3}+ (Cpx = Cp*, 6; Cpxph, 7; Cpxbiph, 8) are readily formed during pH titrations at ca. pH 8.7. Complexes 1 and 3–5 bind strongly to 9-ethylguanine (9-EtG), moderately strongly to 9-methyladenine (9-MeA), and hence preferentially to 9-EtG when in competition with 9-MeA. The extent of guanine and adenine binding to complex 2 was significantly lower for both purines due to steric hindrance from the chelating ligand. All complexes showed potent cytotoxicity, with IC50 values ranging from 6.5 to 0.7 μM toward A2780 human ovarian cancer cells. Potency toward these cancer cells increased with additional phenyl substitution on Cp*: Cpxbiph > Cpxph > Cp*. Cpxbiph with complex 5 exhibited submicromolar activity (2× as active as cisplatin). These data demonstrate how the aqueous chemistry, nucleobase binding, and anticancer activity of C,N-bound IrIII cyclopentadienyl complexes can be controlled and fine-tuned by the modification of the chelating and cyclopentadienyl ligands.

Item Type:	Journal Article
Subjects:	Q Science > QD Chemistry
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Organoiridium compounds, Antineoplastic agents, Ovaries -- Cancer -- Treatment
Journal or Publication Title:	Organometallics
Publisher:	American Chemical Society
ISSN:	0276-7333
Date:	5 August 2011
Volume:	Vol.30
Number:	No.17
Page Range:	pp. 4702-4710
Identification Number:	10.1021/om2005468
Status:	Peer Reviewed
Access rights to Published version:	Restricted or Subscription Access
Funder:	University of Warwick, European Research Council (ERC), Engineering and Physical Sciences Research Council (EPSRC), Overseas Research Students Awards Scheme (ORSAS), European Regional Development Fund (ERDF), Advantage West Midlands (AWM), Birmingham Science City
Grant number:	247450 (ERC)
References:	(1) (a) Medicinal Organometallic Chemistry (Topics in Organometallic Chemistry), 1st ed.; Jaouen, G.; Metzler-Nolte, N., Eds.; Springer-Verlag: Heidelberg, Germany, 2010; Vol. 32. (b) Gasser, G.; Ott, I.; Metzler-Nolte, N. J. Med. Chem. 2011, 54, 3-25. (c) Fish, R. H. Aust. J. Chem. 2010, 63, 1505-1513. (d) Suss-Fink, G. Dalton Trans. 2010, 39, 1673-1688. (e) Dyson, P. J.; Sava, G. Dalton Trans. 2006, 1929-1933. (f) Bruijnincx, P. C. A.; Sadler, P. J. In Advances in Inorganic Chemistry; Rudi van, E., Hubbard, C. D., Eds.; Academic Press: 2009; Vol. 61, pp 1-62. (2) (a) Allen, O. R.; Gott, A. L.; Hartley, J. A.; Hartley, J. M.; Knox, R. J.; McGowan, P. C. Dalton Trans. 2007, 5082-5090. (b) Tan, Y. L. K.; Pigeon, P.; Hillard, E. A.; Top, S.; Plamont, M.-A.; Vessieres, A.; McGlinchey, M. J.; Muller-Bunz, H.; Jaouen, G. Dalton Trans. 2009, 10871-10881. (c) van Rijt, S. H.; Sadler, P. J. Drug Discov. Today 2009, 14, 1089-1097. (d) Strohfeldt, K.; Tacke, M. Chem. Soc. Rev. 2008, 37, 1174-1187. (e) Eger, S.; Immel, T. A.; Claffey, J.; Muller-Bunz, H.; Tacke, M.; Groth, U.; Huhn, T. Inorg. Chem. 2010, 49, 1292-1294. (f) Vessières, A.; Top, S.; Pigeon, P.; Hillard, E.; Boubeker, L.; Spera, D.; Jaouen, G. J. Med. Chem. 2005, 48, 3937-3940. (g) Chatterjee, S.; Biondi, I.; Dyson, P.; Bhattacharyya, A. J. Biol. Inorg. Chem. 2011, 1-10. (h) Hanif, M.; Schaaf, P.; Kandioller, W.; Hejl, M.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G. Aust. J. Chem. 2010, 63, 1521-1528. (3) (a) Liu, Z.; Habtemariam, A.; Pizarro, A. M.; Fletcher, S. A.; Kisova, A.; Vrana, O.; Salassa, L.; Bruijnincx, P. C. A.; Clarkson, G. J.; Brabec, V.; Sadler, P. J. J. Med. Chem. 2011, 54, 3011-3026. (b) Liu, Z.; Salassa, L.; Habtemariam, A.; Pizarro, A. M.; Clarkson, G. J.; Sadler, P. J. Inorg. Chem. 2011, 50, 5777-5783. (c) Schäfer, S.; Sheldrick, W. S. J. Organomet. Chem. 2007, 692, 1300-1309. (d) Sliwinska, U.; Pruchnik, F. P.; Ulaszewski, S.; Latocha, M.; Nawrocka-Musial, D. Polyhedron 2010, 29, 1653-1659. (e) Leung, S.-K.; Kwok, K. Y.; Zhang, K. Y.; Lo, K. K.-W. Inorg. Chem. 2010, 49, 4984-4995. (f) Ali Nazif, M.; Bangert, J.-A.; Ott, I.; Gust, R.; Stoll, R.; Sheldrick, W. S. J. Inorg. Biochem. 2009, 103, 1405-1414. (g) Amouri, H.; Moussa, J.; Renfrew, A. K.; Dyson, P. J.; Rager, M. N.; Chamoreau, L.-M. Angew. Chem., Int. Ed. 2010, 49, 7530-7533. (h) Wirth, S.; Rohbogner, C.; Cieslak, M.; Kazmierczak-Baranska, J.; Donevski, S.; Nawrot, B.; Lorenz, I.-P. J. Biol. Inorg. Chem. 2010, 15, 429-440. (i) Casini, A.; Edafe, F.; Erlandsson, M.; Gonsalvi, L.; Ciancetta, A.; Re, N.; Ienco, A.; Messori, L.; Peruzzini, M.; Dyson, P. J. Dalton Trans. 2010, 39, 5556-5563. (j) Gras, M.; Therrien, B.; Süss-Fink, G.; Casini, A.; Edafe, F.; Dyson, P. J. J. Organomet. Chem. 2010, 695, 1119-1125. (k) Hartinger, C. G. Angew. Chem., Int. Ed. 2010, 49, 8304-8305. (4) (a) Helm, L.; Merbach, A. E. Coord. Chem. Rev. 1999, 187, 151-181. (b) Wilbuer, A.; Vlecken, D. H.; Schmitz, D. J.; Kräling, K.; Harms, K.; Bagowski, C. P.; Meggers, E. Angew. Chem., Int. Ed. 2010, 49, 3839-3842. (5) (a) van Rijt, S. H.; Peacock, A. F. A.; Johnstone, R. D. L.; Parsons, S.; Sadler, P. J. Inorg. Chem. 2009, 48, 1753-1762. (b) Kostrhunova, H.; Florian, J.; Novakova, O.; Peacock, A. F. A.; Sadler, P. J.; Brabec, V. J. Med. Chem. 2008, 51, 3635-3643. (6) White, C. Y., A.; Maitlis, P. M. Inorg. Chem. 1992, 29, 228-234. (7) CrysAlis PRO; Oxford Diffraction Ltd.: Abington, Oxfordshire, U. K., 2007. (8) Sheldrick, G. M. Acta Crystallogr. 1990, A46, 467-473. (9) Sheldrick, G. M. SHELXL-97; University of Göttingen: Göttingen, Germany, 1997. (10) Krezel, A.; Bal, W. J. Inorg. Biochem. 2004, 98, 161-166. (11) Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. J. Natl. Cancer Inst. 1990, 82, 1107-1112. (12) Martin, R. B. In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; VHCA & Wiley-VCH: Zürich, Switzerland, 1999, pp 181-205. (13) (a) Zhang, C. X.; Lippard, S. J. Curr. Opin. Chem. Biol. 2003, 7, 481-489. (b) Deubel, D. V.; Lau, J. K.-C. Chem. Commun. 2006, 2451-2453. (14) Li, L.; Brennessel, W. W.; Jones, W. D. J. Am. Chem. Soc. 2008, 130, 12414-12419. (15) Hohmann, H.; Hellquist, B.; Van Eldik, R. Inorg. Chem. 1992, 31, 345-351. (16) Pizarro, A. M.; Habtemariam, A.; Sadler, P. J. In Medicinal Organometallic Chemistry (Topics in Organometallic Chemistry), 1st ed.; Jaouen, G., Metzler-Nolte, N., Ed.; Springer-Verlag: Heidelberg, Germany, 2010; 32, pp 21-56. (17) Koelle, U. Coord. Chem. Rev. 1994, 135-136, 623-650. (18) Wang, F.; Habtemariam, A.; van der Geer, E. P. L.; Fernández, R.; Melchart, M.; Deeth, R. J.; Aird, R.; Guichard, S.; Fabbiani, F. P. A.; Lozano-Casal, P.; Oswald, I. D. H.; Jodrell, D. I.; Parsons, S.; Sadler, P. J. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18269-18274. (19) (a) Fernández, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Chem.-Eur. J. 2004, 10, 5173-5179. (b) Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Chem.-Eur. J. 2007, 13, 2601-2613. (20) (a) Peacock, A. F. A.; Habtemariam, A.; Fernández, R.; Walland, V.; Fabbiani, F. P. A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. J. Am. Chem. Soc. 2006, 128, 1739-1748. (b) Peacock, A. F. A.; Parsons, S.; Sadler, P. J. J. Am. Chem. Soc. 2007, 129, 3348-3357. (c) Kljun, J.; Bytzek, A. K.; Kandioller, W.; Bartel, C.; Jakupec, M. A.; Hartinger, C. G.; Keppler, B. K.; Turel, I. Organometallics 2011, 30, 2506-2512. (21) Pullman, B.; Pullman, A. Biochimica et Biophysica Acta 1959, 36, 343-350. (22) Baik, M.-H.; Friesner, R. A.; Lippard, S. J. J. Am. Chem. Soc. 2003, 125, 14082-14092. (23) Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Inorg. Biochem. 2007, 101, 1903-1912. (24) (a) Atwell, G. J.; Bos, C. D.; Baguley, B. C.; Denny, W. A. J. Med. Chem. 1988, 31, 1048-1052. (b) Atwell, G. J.; Baguley, B. C.; Denny, W. A. J. Med. Chem. 1989, 32, 396-401. (25) (a) Morris, R. E.; Aird, R. E.; del Socorro Murdoch, P.; Chen, H.; Cummings, J.; Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; Sadler, P. J. J. Med. Chem. 2001, 44, 3616-3621. (b) Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I. Br. J. Cancer 2002, 86, 1652-1657.
URI:	http://wrap.warwick.ac.uk/id/eprint/36984